BiVictriX Therapeutics Passes Key Resolutions

BiVictriX Therapeutics PLC (GB:BVX) has released an update.

BiVictriX Therapeutics PLC, a biotech company specializing in next-generation cancer treatments, has successfully passed all resolutions at their recent General Meeting, leading to the delisting from AIM and transition to a private company. The transition will be facilitated by a new matched bargain facility provided by JP Jenkins post-delisting. Shareholders approved the delisting and restructuring plans, which are set to enhance the company’s focus on developing their pioneering Bi-Cygni® ADCs for cancer therapy.

For further insights into GB:BVX stock, check out TipRanks’ Stock Analysis page.